Clinical trial · Interventional
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients Treated for B-cell Lymphoma or Hodgkin Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the feasibility of predicting patient outcomes at 1 year and 2 years after the end of first-line treatment using "liquid biopsy" (monitoring of circulating tumor DNA, ctDNA), compared to the currently recommended examination, which is Positon Emission Tomography (PET-CT) imaging at the end of first-line treatment (assessment of therapeutic response using the Deauville score according to the Lugano 2014 criteria). The study will focus on demonstrating the ability of ctDNA clearance to predict 1-year and 2-year outcomes (lymphoma progression or death) in patients treated with first-line therapy for B-cell lymphoma or Hodgkin lymphoma. This could contribute to establishing minimal residual disease clearance as a key endpoint for evaluating the efficacy of therapeutic strategies in future clinical trials and guiding patient management (e.g., de-escalation or intensification strategies, redirection toward immunotherapy, and theranostic approaches).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B-cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- CELERITY Arm
- description
- CT DNA Collection at baseline, mid-treatment and at the end of treatment
- interventionNames
- Other: Blood assessment
Primary outcomes (1)
- measure
- Evaluation of the diagnostic performance of minimal residual disease (MRD) at the end of treatment in terms of sensitivity, specificity, positive predictive value, and negative predictive value for predicting 1-year progression-free survival (PFS).
- timeFrame
- 1 year
- description
- Comparison with the diagnostic performance of PET-CT imaging at the end of first-line treatment for predicting 1-year PFS
Secondary outcomes (2)
- measure
- Response rates
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient aged 18 years or older * Diagnosed with large B-cell lymphoma (including T-cell/histiocyte-rich B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma), follicular B-cell lymphoma (all grades), mantle cell lymphoma (all variants), marginal zone B-cell lymphoma, or Hodgkin lymphoma (classical Hodgkin lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma) * Indication for first-line systemic treatment with chemotherapy or chemoimmunotherapy * Has signed the study-specific informed consent form * Pre-treatment PET-CT scan performed * Patient is affiliated with or a beneficiary of a health insurance plan Exclusion Criteria: * Pregnant or breastfeeding woman * Patient who has already started first-line chemotherapy or chemoimmunotherapy for lymphoma treatment (prephase corticosteroid therapy is allowed) * Patient enrolled in a clinical trial evaluating an early-phase therapeutic agent (Phase I-II) * Patient weighing less than 30 kg * Adult under legal protection measures * Patient unable to understand the study for any reason or unable to comply with the trial requirements (e.g., language barrier, psychological, or geographic issues).
References
Publications (0)
Data not yet available